Farisil (chlorhexidine, benzocaine) lozenges №20


Manufacturer: Spain

Local treatment of acute infectious and inflammatory diseases of the mouth and throat.



Farisil lozenges Composition
active ingredients: chlorhexidine, benzocaine;

1 tablet contains chlorhexidine dihydrochloride 5 mg, benzocaine 5 mg;

Farisil lozenges excipients: mannitol (E 421), microcrystalline cellulose, povidone, magnesium stearate, sodium cyclamate, sodium saccharin, orange flavor or lemon flavor, menthol flavor.

Dosage form
Lozenges, orange or lemon flavored.

Basic physical and chemical properties: yellowish-white tablets, round, with a beveled edge and a line on one side.

Pharmacotherapeutic group
Throat medications. Antiseptics. ATX code R02A A.

Farisil is a combined antiseptic preparation for topical use in infectious and inflammatory diseases of the oral cavity and throat. The action of the drug is provided by the action of the components that make up the drug.

Chlorhexidine is an antiseptic agent, the action of which is due to surface cationic properties, which leads to a violation of the integrity of the membranes of microorganisms. The drug is active against many bacteria, fungi and viruses, causes a microbicidal effect.

Benzocaine, which is part of the drug, has a local anesthetic (analgesic) effect. Reduces sore throat, perspiration, pain when swallowing.

Approximately 30% of chlorhexidine is absorbed in the oral cavity, excreted with saliva during the day, which significantly prolongs its effect. Benzocaine is almost not absorbed in the oral cavity.

Local treatment of acute infectious and inflammatory diseases of the mouth and throat.

Hypersensitivity to chlorhexidine, benzocaine or other components of the drug or other drugs with anesthetic activity. Phenylketonuria.

Interaction with other medicinal products and other types of interactions
The drug should not be used with other local antiseptics. It should be borne in mind that benzocaine metabolites significantly weaken the antibacterial effect of sulfonamide derivatives.

Simultaneous use with preparations containing iodine is not recommended. The drug, due to the presence of benzocaine, interacts with cholinesterase inhibitors, which suppress the metabolism of local anesthetics, therefore there is an increased risk of systemic toxicity.

Interaction with diagnostic tests.

Interactions with pancreatic diagnostic tests that use benthromide may occur. The results are not validated because benzocaine is metabolized by arylamines and also increases the amount of PABA (PABA). It is recommended to stop treatment at least 3 days before the test.

Application features
Patients with intolerance to ether-type anesthetics (novocaine), parabens may also not tolerate benzocaine. The drug should be used with caution in children, elderly patients and seriously ill patients, since they are more sensitive to benzocaine and exceeding the dose can lead to methemoglobinemia. The tablets should not be bitten or swallowed, since the effect of the drug is local and is possible only with direct contact with the affected area.

With the use of local anesthetics, including benzocaine, there is an increased risk of systemic toxicity in acute illness. In patients with hypersensitivity to local anesthetics of the ester type (especially derivatives of para-aminobenzoic acid (PABA), parabens, or paraphenyldiamine (hair dye)), hypersensitivity to benzocaine may also be determined.